Bain Capital Life Sciences Investors’s C4 Therapeutics CCCC Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.5M	Hold	7,171,910	–	–	1.99%	13
2026 Q1	$18.9M	Hold	7,171,910	–	–	1.7%	15
2025 Q4	$13.7M	Buy	7,171,910 +6,060,000	+545%	+$14.4M	1.05%	14
2025 Q3	$2.47M	Hold	1,111,910	–	–	0.16%	19
2025 Q2	$1.59M	Hold	1,111,910	–	–	0.2%	20
2025 Q1	$1.78M	Hold	1,111,910	–	–	0.26%	21
2024 Q4	$4M	Hold	1,111,910	–	–	0.47%	21
2024 Q3	$6.34M	Hold	1,111,910	–	–	0.66%	18
2024 Q2	$5.14M	Sell	1,111,910 -30,300	-3%	-$181K	0.56%	19
2024 Q1	$9.33M	Sell	1,142,210 -500,000	-30%	-$3.88M	0.75%	20
2023 Q4	$9.28M	Hold	1,642,210	–	–	0.89%	19
2023 Q3	$3.05M	Hold	1,642,210	–	–	0.34%	29
2023 Q2	$4.52M	Hold	1,642,210	–	–	0.47%	28
2023 Q1	$5.16M	Hold	1,642,210	–	–	0.64%	29
2022 Q4	$9.69M	Hold	1,642,210	–	–	1.08%	23
2022 Q3	$14.4M	Hold	1,642,210	–	–	1.72%	18
2022 Q2	$12.4M	Hold	1,642,210	–	–	1.45%	17
2022 Q1	$39.8M	Hold	1,642,210	–	–	3.87%	9
2021 Q4	$52.9M	Buy	1,642,210 +1	+0%	+$40	4.19%	8
2021 Q3	$73.4M	Hold	1,642,209	–	–	4.55%	8
2021 Q2	$62.1M	Hold	1,642,209	–	–	4.07%	7
2021 Q1	$60.7M	Hold	1,642,209	–	–	3.44%	8
2020 Q4	$54.4M	Buy	+1,642,209	New	+$47.6M	3.42%	8

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bain Capital Life Sciences Investors's CCCC Position: Q2 2026 in Review

Bain Capital Life Sciences Investors held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 7,171,910 shares worth $33.5M. The position accounts for 1.99% of the portfolio, ranked #13.

Bain Capital Life Sciences Investors first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $73.4M in Q3 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Bain Capital Life Sciences Investors held 7,171,910 shares of C4 Therapeutics worth $33.5M as of Q2 2026.
Bain Capital Life Sciences Investors left its C4 Therapeutics share count unchanged in Q2 2026.
C4 Therapeutics made up 1.99% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #13 holding.
Bain Capital Life Sciences Investors first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
Bain Capital Life Sciences Investors's C4 Therapeutics position peaked at $73.4M in Q3 2021.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.